Liquidia (LQDA) Price Prediction: $130 Bull, $70 Bear
By Tobi Opeyemi Amure
AI summary of the source article
On September 30, 2026, Liquidia stock dropped 57.19 percent to close at $30.26 after Judge Richard G. Andrews ruled that claims 1 and 14 of United Therapeutics' U.S. Patent No. 11,826,327 were valid and infringed. United Therapeutics seeks damages and an order for the FDA to withdraw Yutrepia's approval until a label omitting PH-ILD is approved. Liquidia stated it will appeal and seek to strip PH-ILD from the label itself. Following the ruling, Needham cut its target to $70, while an earlier H.C. Wainwright bull target sat at $130.
Why it matters
The ruling could force Yutrepia off the U.S. market until the FDA approves an edited label, significantly threatening Liquidia's sales and subjecting the company to potential past damages.
Key facts
- Liquidia shares dropped 57.19 percent to $30.26 on September 30, 2026, erasing about $3.62 billion in market value.
- A Delaware court ruled that claims 1 and 14 of United Therapeutics' '327 patent covering PH-ILD treatment are valid and infringed.
- Liquidia announced plans to appeal the decision and request that the FDA remove the PH-ILD indication from Yutrepia's label.